The Philippine Health Insurance Corporation (PhilHealth) endorsed five 'better benefit packages' for heart attacks, rare ...

The Department of Health (DOH) on Friday, Nov. 15, announced that the Benefits Committee (BenCom) of the Philippine Health ...

11.3. The Advisory Committee recommended that avalglucosidase alfa for the treatment of late onset Pompe disease be funded with a medium priority.

Amicus Therapeutics Inc (FOLD) reports a 37% revenue increase and raises full-year guidance, despite ongoing litigation challenges.

In the preceding three months, 8 analysts have released ratings for Amicus Therapeutics FOLD, presenting a wide array of ...

This would be with respect to Pombiliti [cipaglucosidase alfa-atga] + Opfolda [miglustat] having been approved for the treatment of adults with late-onset Pompe Disease. The truth is that there is ...

Their results argue for a change to parity between small-molecule agents and biologics when it comes to Inflation Reduction ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that AB ...

Q3 2024 Earnings Call Transcript November 6, 2024 Amicus Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Group 3 covers conditions like Gaucher Disease and Pompe Disease, where treatment is available but complicated by high costs ...